(XPH) S&P Pharmaceuticals - Overview
Etf: Pharmaceutical Stocks, Index, Sampling Strategy, Market Capitalization
Dividends
| Dividend Yield | 1.00% |
| Yield on Cost 5y | 0.90% |
| Yield CAGR 5y | 1.39% |
| Payout Consistency | 89.5% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 23.0% |
| Relative Tail Risk | 0.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.99 |
| Alpha | 13.71 |
| Character TTM | |
|---|---|
| Beta | 0.734 |
| Beta Downside | 0.797 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.57% |
| CAGR/Max DD | 0.50 |
Description: XPH S&P Pharmaceuticals January 18, 2026
The SPDR S&P Pharmaceuticals ETF (ticker XPH) seeks to replicate the performance of the S&P Pharmaceuticals Select Industry Index by using a sampling methodology; it must hold at least 80 % of its assets in the index constituents, aiming for tight tracking while allowing for efficient portfolio construction.
Key fund attributes: U.S.-based, classified in the Health-ETF category, with a typical expense ratio around 0.35 % and an average daily trading volume exceeding 200,000 shares, which together support reasonable liquidity for institutional and retail investors.
Sector fundamentals that drive XPH’s underlying holdings include: (1) global R&D intensity-pharma firms on average spend roughly 20 % of revenue on research, a leading indicator of pipeline strength; (2) regulatory milestones-FDA approval rates and patent cliffs directly affect earnings volatility; and (3) macro-demographic trends-aging populations in North America and Europe underpin long-term demand for prescription drugs, supporting revenue growth rates of 5-7 % YoY across the sector.
For a deeper, data-rich assessment of XPH’s valuation and risk profile, you may find the analytics on ValueRay worth exploring.
What is the price of XPH shares?
Over the past week, the price has changed by +3.32%, over one month by +3.19%, over three months by +18.10% and over the past year by +27.76%.
Is XPH a buy, sell or hold?
What are the forecasts/targets for the XPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 60.4 | 5.5% |
XPH Fundamental Data Overview February 03, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 264.2m USD (264.2m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 264.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 264.2m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.62% (E(264.2m)/V(264.2m) * Re(8.62%) + (debt-free company))
Discount Rate = 8.62% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)